title: [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
abstract: Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.
authors.forename: A A
authors.initials: AA
authors.lastname: Zozulia
authors.forename: G G
authors.initials: GG
authors.lastname: Neznamov
authors.forename: T S
authors.initials: TS
authors.lastname: Siuniakov
authors.forename: N V
authors.initials: NV
authors.lastname: Kost
authors.forename: M V
authors.initials: MV
authors.lastname: Gabaeva
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Sokolov
authors.forename: E V
authors.initials: EV
authors.lastname: Serebriakova
authors.forename: O A
authors.initials: OA
authors.lastname: Siranchieva
authors.forename: A V
authors.initials: AV
authors.lastname: Andriushenko
authors.forename: E S
authors.initials: ES
authors.lastname: Telesheva
authors.forename: S A
authors.initials: SA
authors.lastname: Siuniakov
authors.forename: A B
authors.initials: AB
authors.lastname: Smulevich
authors.forename: N F
authors.initials: NF
authors.lastname: Miasoedov
authors.forename: S B
authors.initials: SB
authors.lastname: Seredenin
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001008:Anxiety Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D015415:Biomarkers / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004745:Enkephalins / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008472:Medazepam / Q000008:administration & dosage / Q000493:pharmacokinetics; D008875:Middle Aged; D009440:Neurasthenia / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D009842:Oligopeptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011594:Psychometrics / Q000379:methods; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D015415:Biomarkers; D004745:Enkephalins; D009842:Oligopeptides; D008472:Medazepam; C100827:TP 7